Resources

It’s Spring Statement week and we have a webinar on what it means for the sector this Friday; also in this blog - why VPAG needs sorting and a new Series C raise for a BIA member, Brainomix.

In this blog, BIA CEO Steve Bates OBE gives his take on the announcement that the UK government is consulting on introducing a new law to raise the Statutory Scheme payment rate for newer branded medicines from 15.5% to 32.2% of subject companies' NHS sales revenues in the second half of 2025.

A big raise as next generation biotech leaders gather, NHS England is abolished, and global trade disputes touch on our industry.

The UKHSA Conference 2025, delivered in partnership with the FPH, will explore the full breadth of UKHSA’s work; from science-driven research to effective policy implementation.

Rare Disease Day marks an important occasion to raise awareness of rare diseases and the need for action to support people and families living with these conditions.

The Institute of Clinical Research (ICR) is proud to now be a Networking Member of the BIA.

RQ Bio welcomes positive CHMP opinion on Kavigale for prevention of COVID-19 in immunocompromised individuals

Patients, the NHS and the Life Sciences sector set to benefit from new clinical trials framework being laid in parliament today.

Yourgene Health (part of the Novacyt group of companies), a leading international molecular diagnostics group, announces that it has received accreditation under the new EU requirements of the in vitro diagnostic regulation (IVDR) for the Yourgene® Cystic Fibrosis Base assay.

With a new Labour Government in place, this year’s event set the stage for impactful collaboration with MPs and policymakers. Read on to learn how we’re keeping life sciences at the top of the agenda.

AUCATZYL is the first CAR T therapy approved by the FDA with no requirement for a REMS program (Risk Evaluation Mitigation Strategy); Approval based on FELIX clinical trial of obe-cel in adult patients with r/r B-ALL

New data shows investing in life sciences produces great returns, London Life Sciences Week and #bioProcessUK are nearly here.

The first Budget of the new government will be presented this Wednesday. It’s an important moment, not just for life sciences but for the broader UK economy. Read this blog for an update on the Life Sciences Council, and the launch of our latest Influencing and shaping our sector report.

Landmark studies represent the largest investigational trials to be conducted to date for cannabinoids as a treatment for refractory epilepsy.

Steve Bates OBE, CEO of the BIA, responded to the announcement of a new Regulatory Innovation Office.